Medical Policy
Signal-Averaged Electrocardiography (SAECG)

Table of Contents
- Policy: Commercial
- Coding Information
- Policy: Medicare
- Description
- Authorization Information
- Policy History
- Information Pertaining to All Policies
- References

Policy Number: 134
BCBSA Reference Number: 2.02.04
NCD/LCD: Signal Averaged Electrocardiography (Sa-Ecg) (L7171)

Related Policies
None

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Signal-averaged ECG (SAECG) is INVESTIGATIONAL, including, but not limited to, its use for the following indications:
- As a technique of risk stratification for arrhythmias after prior myocardial infarction
- In patients with cardiomyopathy
- In patients with syncope;
- As an assessment of success after surgery for arrhythmia
- In the detection of acute rejection of heart transplants
- As an assessment of efficacy of antiarrhythmic drug therapy, or
- In the assessment of success of pharmacological, mechanical, or surgical interventions to restore coronary artery blood flow.

Medicare HMO BlueSM and Medicare PPO BlueSM Members

LMRP for Signal Averaged Electrocardiography (Sa-Ecg) (L7171)

Prior Authorization Information
Inpatient
- For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.

Outpatient
- For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient.
Outpatient

<table>
<thead>
<tr>
<th>Commercial Managed Care (HMO and POS)</th>
<th>This is not a covered service.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>This is not a covered service.</td>
</tr>
<tr>
<td>Medicare HMO BlueSM</td>
<td>Prior authorization is not required.</td>
</tr>
<tr>
<td>Medicare PPO BlueSM</td>
<td>Prior authorization is not required.</td>
</tr>
</tbody>
</table>

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The following CPT code is considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

**CPT Codes**

<table>
<thead>
<tr>
<th>CPT codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>93278</td>
<td>Signal-averaged electrocardiography (SAECG), with or without ECG</td>
</tr>
</tbody>
</table>

**Description**

Signal-averaged electrocardiography (SAECG) is a more detailed type of ECG involving computerized analysis of small segments of a standard EKG to detect abnormalities, termed ventricular late potentials (VLPs). These late-potentials are associated with delayed activation of the ventricles, and can aid in the identification of a population of patients at an increased risk for ventricular tachycardia. Therefore, VLPs, as measured by SAECG, have been investigated as a risk factor for arrhythmic events in patients with a variety of cardiac conditions, including cardiomyopathy and prior history of myocardial infarction (MI).

Patients considered at high risk of ventricular arrhythmias, and thus sudden death, may be treated with drugs to suppress the emergence of arrhythmias or implantable cardiac defibrillators to promptly detect and terminate tachyarrhythmias when they occur. Because sudden cardiac death, whether from arrhythmias or pump failure, is one of the most common causes of death after a previous MI, there is intense interest in risk stratification to target therapy.

This policy does not address other risk stratification methods, such as T-wave alternans.

**Summary**

Signal-averaged ECG has some ability to risk-stratify patients at risk for ventricular arrhythmias. However, this predictive ability is modest, and this technique has not been used to stratify patients into clinically relevant categories of risk. Some RCTs have used signal-averaged ECG for selection of patients at high risk of ventricular arrhythmias, but these studies have not demonstrated outcome benefits for the treatments under study. Signal-averaged ECG has also been tested as a diagnostic test for a variety of cardiac-related disorders, but the evidence is insufficient to demonstrate clinical utility for any of the conditions tested. Therefore, signal-averaged ECG has not demonstrated improvements in health outcomes and is investigational for all indications for commercial members.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/2020</td>
<td>Policy updated with literature review through January 1, 2020, references added.</td>
</tr>
</tbody>
</table>
Information Pertaining to All Blue Cross Blue Shield Medical Policies
Click on any of the following terms to access the relevant information:
Medical Policy Terms of Use
Managed Care Guidelines
Indemnity/PPO Guidelines
Clinical Exception Process
Medical Technology Assessment Guidelines

References


